Financial reports
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
10-K
2021 FY
Annual report
29 Mar 22
10-Q
2021 Q3
Quarterly report
15 Nov 21
Current reports
8-K
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
28 Mar 24
8-K
Other Events
23 Feb 24
8-K
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
20 Feb 24
8-K
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
12 Feb 24
8-K
Over 40 sites (U.S. and Canada) have agreed to participate in the LEVEL study
8 Feb 24
8-K
Other Events
6 Feb 24
8-K
Other Events
19 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Jan 24
8-K
Tenax Therapeutics Announces Reverse Stock Split
5 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
1 Dec 23
Registration and prospectus
POS AM
Prospectus update (post-effective amendment)
11 Apr 24
POS AM
Prospectus update (post-effective amendment)
11 Apr 24
424B3
Prospectus supplement
26 Feb 24
424B3
Prospectus supplement
26 Feb 24
424B3
Prospectus supplement
21 Feb 24
424B3
Prospectus supplement
21 Feb 24
424B3
Prospectus supplement
13 Feb 24
424B4
Prospectus supplement with pricing info
9 Feb 24
424B3
Prospectus supplement
8 Feb 24
424B3
Prospectus supplement
6 Feb 24
Proxies
DEFA14A
Additional proxy soliciting materials
27 Oct 23
DEF 14A
Definitive proxy
27 Oct 23
PRE 14A
Preliminary proxy
16 Oct 23
DEFA14A
Additional proxy soliciting materials
1 Jun 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
PRE 14A
Preliminary proxy
13 Apr 22
Other
EFFECT
Notice of effectiveness
15 Apr 24
EFFECT
Notice of effectiveness
15 Apr 24
EFFECT
Notice of effectiveness
8 Feb 24
CORRESP
Correspondence with SEC
5 Feb 24
CORRESP
Correspondence with SEC
5 Feb 24
CORRESP
Correspondence with SEC
1 Feb 24
UPLOAD
Letter from SEC
7 Dec 23
UPLOAD
Letter from SEC
16 Aug 23
CORRESP
Correspondence with SEC
10 Aug 23
UPLOAD
Letter from SEC
7 Aug 23
Ownership
SC 13G
S.H.N. Financial Investments Ltd.
20 Feb 24
SC 13G
CVI Investments, Inc.
16 Feb 24
SC 13G
Lind Global Fund II LP
15 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
3
LAWRENCE R HOFFMAN
12 Jan 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G
INTRACOASTAL CAPITAL, LLC
13 Feb 23
SC 13D/A
Rich Stuart
9 Feb 23
SC 13D/A
Doogan Declan
9 Feb 23
SC 13D/A
Rich Stuart
6 Jan 23